(Q37818256)

23 August 2017

1 reference

title

Investigational antibody-drug conjugates for hematological malignancies (English)

1 reference

23 August 2017

1 reference

Andrew G Polson

1

1 reference

23 August 2017

William Y Ho

series ordinal

2

1 reference

23 August 2017

Vanitha Ramakrishnan

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

11 December 2010

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

75-85

1 reference

Potent antibody drug conjugates for cancer therapy

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Antibody-drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Arming antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Targeted drug conjugates: principles and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Drug-conjugated monoclonal antibodies for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Evolving approaches to primary treatment of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Safety of rituximab maintenance therapy in follicular lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

ITAMs versus ITIMs: striking a balance during cell regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Aberrant expression and reverse signalling of CD70 on malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Contribution of linker stability to the activities of anticancer immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Toward an effective targeted chemotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

CD74 is expressed by multiple myeloma and is a promising target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.539557

10.1517/13543784.2011.539557

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference